Wednesday June 26, 2019 0 comments
LONGMONT -- KromaTiD, Inc. announced the appointment of Christopher Tompkins as CEO.
Tompkins, who joined the company in 2010, most recently served as president, GM and chief technology officer. He has 25 years of pharmaceutical and biotechnology industry experience focused in the areas of process development, operations and the commercialization of new technologies.
With the appointment of Tompkins to CEO, KromaTiD said it is taking a key step in the process of strategic alignment with the therapeutic gene editing market.
"Through recent milestones including several new strategic customer relationships, an SBIR Phase 2 grant award and successful fundraising, KromaTiD has successfully validated the market potential of our dGH platform, especially as it applies to structural genomic measurements critical to the gene editing field," said Tompkins.
"I am pleased and privileged as the CEO to have the opportunity to lead the KromaTiD team as our company embarks on this period of high growth. This will include management, core and advisory team additions to further ensure the successful execution of our mission."
KromaTiD said its mission is to transform the fields of gene editing, undiagnosed disease and oncology through discovery and measurement of structural genomic changes.